Skip to content

Advertisement

  • Correction
  • Open Access

Correction to: Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy

  • 1Email author,
  • 2,
  • 3,
  • 3,
  • 1, 4,
  • 5,
  • 6,
  • 7,
  • 8,
  • 9 and
  • 9
BMC Cancer201818:413

https://doi.org/10.1186/s12885-018-4200-5

  • Published:

The original article was published in BMC Cancer 2018 18:225

Correction

It has been highlighted that in the original manuscript [1] Table S3 ‘An example of the predictive computational modeling process. Specific details on an annexure section of the PD-L1 pathway show the step-by-step reactions, mechanisms, and reaction equations that occur. Such reactions also occurred in all of the other pathways’ was omitted and did not appear in the Additional files. The original article has been updated.

Notes

Declarations

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Iowa Institute for Oral Health Research, College of Dentistry, The University of Iowa, 801 Newton Road, Iowa City, IA 52242, USA
(2)
Cellworks Research India Ltd., Whitefield, Bangalore, 560066, India
(3)
Biomedical Engineering, The University of Iowa, 5318 SC, Iowa City, IA 52242, USA
(4)
Division of Biostatistics and Research Design, College of Dentistry, The University of Iowa, 801 Newton Road, Iowa City, IA 52242, USA
(5)
Division of Hematology/Oncology, Columbia University Medical Center, 177 Fort Washington Avenue, New York, NY 10032, USA
(6)
Molecular Pathology Laboratory, Department of Pathology, University of Iowa Hospitals and Clinics, 200 Hawkins Dr., C606GH, Iowa City, IA 52242, USA
(7)
Clinical Services, Experimental Therapeutics, Melanoma and Sarcoma Program, Holden Comprehensive Cancer Center, The University of Iowa, Iowa City, IA 52242, USA
(8)
Department of Radiation Oncology, Human Oncology and Pathogenesis Program, Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
(9)
Cellworks Group, Inc., 2033 Gateway Place Suite 500, San Jose, CA 95110, USA

Reference

  1. Brogden KA, et al. Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy. BMC Cancer. 2018;18:225. https://doi.org/10.1186/s12885-018-4134-y.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s). 2018

Advertisement